Leaflet: Information for the User
Entecavir Kern Pharma1Film-coated Tablets EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
1. What isEntecavirKern Pharma and what it is used for
2. What you need to know before you start takingEntecavirKern Pharma
3. How to takeEntecavirKern Pharma
4. Possible side effects
5. Storage ofEntecavirKern Pharma
6. Contents of the pack and additional information
Entecavir is an antiviral medication used to treat chronic (long-term) infection by the hepatitis B virus (HBV) in adults.Entecavir may be used in patients whose liver is damaged but still functioning properly (compensated liver disease) and in patients whose liver is damaged and not functioning properly (decompensated liver disease).
Entecavir is also used to treat chronic (long-term) infection by HBV in children and adolescents from 2 years to less than 18 years.Entecavir may be used in children whose liver is damaged but still functioning properly (compensated liver disease).
Hepatitis B infection can damage the liver. Entecavir reduces the amount of virus in the body and improves the liver condition.
Do not take Entecavir Kern Pharma
Warnings and precautions
Consult your doctor or pharmacist before starting to take entecavir.
You should not take entecavir for the treatment of your hepatitis B infection unless you are also taking medications for the treatment of HIV infection, as otherwise, the effectiveness of future HIV treatments may be reduced. Entecavir will not control your HIV infection.
Children and adolescents
Entecavir should not be used in children under 2 years of age or weighing less than 10 kg.
Entecavir Kern Pharma with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Entecavir Kern Pharma with food and drinks
In most cases, you can take entecavir with or without food. However, if you have received previous treatment with another medication containing lamivudine as the active ingredient, consider the following. If you have switched to entecavir because lamivudine treatment was unsuccessful, take entecavir on an empty stomach, once a day. If your liver disease is advanced, your doctor will also instruct you on taking entecavir on an empty stomach. Empty stomach means at least 2 hours after and 2 hours before the next meal.
Children and adolescents (2 to less than 18 years of age) can take entecavir with or without food.
Pregnancy, breastfeeding, and fertility
Inform your doctor if you are pregnant or plan to become pregnant. Entecavir use has not been proven to be safe during pregnancy. Do not use entecavir during pregnancy unless it is clearly necessary, according to your doctor. It is essential for women of childbearing age who are being treated with entecavir to use an effective contraceptive method to avoid becoming pregnant.
Do not breastfeed during treatment with entecavir. If you are breastfeeding, inform your doctor. It is unknown whether entecavir, the active ingredient in this medication, is excreted in breast milk.
Driving and operating machinery
Dizziness, fatigue, and drowsiness are common side effects that may impair your ability to drive and operate machinery. If you have any doubts, consult your doctor.
Entecavir Kern Pharma contains lactose
This medication contains lactose. If your doctor has indicated that you have an intolerance to certain sugars, consult with them before taking this medication.
All patients do not need to take the same dose of entecavir.
Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
For adultsthe recommended dose is 0.5 mg or 1 mg once a day (oral administration).
Your dose will depend on:
For children and adolescents(from 2 to less than 18 years of age), your pediatrician will decide on the appropriate dose based on the child's body weight.
Entecavir is available in 0.5 mg tablets and may be available in oral solution.
Your doctor will advise you on what dose is correct for you. Always take the dose recommended by your doctor to ensure the medication is fully effective and to reduce the development of treatment resistance. Take entecavir for the entire time your doctor has indicated. Your doctor will tell you when to stop treatment
Some patients must take this medication on an empty stomach (see Entecavir with food and drinksin Section 2). If your doctor tells you to take this medication on an empty stomach, empty stomach means at least 2 hours after a meal and 2 hours before the next meal.
If you take more Entecavir Kern Pharma than you should
If you have taken more entecavir than you should, consult your doctor, pharmacist, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount used.
If you forgot to take Entecavir Kern Pharma
It is essential not to forget any dose. If you forget a dose of entecavir, you should take it as soon as possible and then take the next scheduled dose at the usual time. If it is almost time for your next dose, do not take the missed dose. Wait and take the next dose at the usual time. Do not take a double dose to compensate for the missed doses.
Do not interrupt treatment with Entecavir Kern Pharma without consulting your doctor
Some people develop severe hepatitis symptoms when stopping entecavir treatment. Inform your doctor immediately of any changes in symptoms you observe after stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Adults
Patients treated with entecavir have reported the following adverse effects:
Children and Adolescents
The adverse effects experienced by children and adolescents are similar to those experienced by adults as described above with the following difference:
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Blister: This medication does not require special storage conditions.
Bottle: This medication does notrequire special storage conditions.
Medicines should not be disposed of through the drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.
Composition of Entecavir Kern Pharma
Core of the tablet:lactose monohydrate, microcrystalline cellulose, crospovidone (type A) (E1202), anhydrous ethanol and magnesium stearate.
Film coating: Opadry II white 85F28751 containing polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol/PEG 3000 (E1521) and talc (E553b).
Appearance of the product and contents of the package
Entecavir Kern Pharma 0.5 mg film-coated tablets are white or off-white and triangular in shape. They are marked with “ENT” on one face and with “0.5” on the other face.
They are supplied in boxes containing 30 or 30 x 1 film-coated tablets in Alu/Alu blisters or in Alu/Alu single-dose blisters, respectively, and in bottles containing 30 film-coated tablets.
Only some package sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Kern Pharma, S.L.
Venus, 72 - Pol. Ind.Colón II
08228 Terrassa - Barcelona
Spain
Responsible for manufacturing:
PHARMASCIENCE INTERNATIONAL LIMITED
1st floor Iacovides Tower
81-83 Griva Digeni Avenue,
1090 NicosiaCyprus
This medicine is authorized in the member states of the European Economic Area with the following names:
Spain :Entecavir Kern Pharma 0.5 mg film-coated tablets
Bulgaria:?????????Pharmascience International Ltd 0.5 mg ????????? ????????
Hungary:Entecavir Pharmascience International Ltd 0,5 mg filmtabletta
Last review date of this leaflet: July 2022
Detailed and updated information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.